Shares of Novavax, Inc. (NVAX) skyrocketed nearly 99% on Friday after announcing a multi-billion-dollar deal with pharma giant Sanofi (SNY) for its protein-based COVID-19 vaccine, Nuvaxovid. Sanofi Deal Breathes New Life Beginning next year, Sanofi will gain rights to co-market Nuvaxovid globally, except in certain countries where Novavax has existing partnership agreements. The French drugmaker also has the sole license to develop and market the Novavax vaccine in combination with its influenza vaccine. In ...